Stabilizing the Molecules Medicine Left Behind
A university-originated pharmaceutical platform advancing stabilized acidic cannabinoid therapeutics through coordination chemistry for neurological disease.
CU Boulder Spin-Off · Boulder, Colorado
Platform Stage
Preclinical
IND-Aligned
Therapeutic Area
Neurology
CNS Focus
Manufacturing
GMP-Ready
Kilogram Scale
IP Foundation
University
Patent-Backed
Coordination-Based Stabilization
Acidic cannabinoids demonstrate differentiated pharmacological activity across neurological and inflammatory pathways. However, spontaneous chemical instability has historically prevented advancement under global pharmaceutical standards.
The Translational Barrier
Without long-term stability and batch reproducibility, compounds cannot progress into regulated clinical development — blocking a promising therapeutic class.
AltaSolvix Platform
Our coordination-based stabilization science extends compound shelf life and enables pharmaceutical-grade manufacturing consistency across multiple acidic cannabinoid assets.
GMP Compatible
Designed for pharmaceutical-grade manufacturing at kilogram scale
ICH Aligned
Stability validation under international regulatory standards
Multi-Asset
Scalable platform architecture across multiple compounds
Advancing Toward Clinical Translation
Our lead program targets neurological disorders with significant unmet medical need, advancing through disciplined, regulatory-grade development.
Stabilized Acidic Cannabinoid — CNS
Targeting neurological conditions where acidic cannabinoids demonstrate differentiated pharmacological activity. Development follows structured IND-aligned milestones with regulatory strategy integrated from inception.
Stabilized
Validated
Underway
Planned
Measured Progress Toward Clinical Readiness
AltaSolvix advances through defined technical inflection points anchored in regulatory standards and manufacturing validation. Each phase reduces scientific and operational risk while building scalable platform infrastructure.
Lead Program
Neurology — CNS
Stabilized acidic cannabinoid advancing through structured preclinical development
Platform Assets
Multiple Indications
Additional stabilized cannabinoid compounds in early characterization
Future Development
Expansion Pipeline
IND-enabling roadmap for lead and follow-on candidates
PlannedKilogram-scale GMP-compatible batch production
High-purity analytical validation
Long-term stability program underway
Regulatory-aligned development framework
Multi-source funding engagement
Anchored in Academic Innovation
AltaSolvix was formed as a University of Colorado Boulder spin-off and continues to collaborate closely with university researchers to advance stabilization science into structured pharmaceutical development.
University-Originated IP
Patent-backed innovation from CU Boulder research
Translational Leadership
Bridging academic discovery to pharmaceutical development
Regulatory Strategy
IND-aligned framework with CMC architecture from day one
Commercialization Expertise
Disciplined execution toward durable clinical translation
Mission
To modernize drug development by eliminating inefficiency, compressing timelines, and upholding uncompromising regulatory standards — because delays cost both patients and value.
Vision
A world where scientifically promising therapies advance efficiently — freed from operational waste and structural friction.
Academic discovery. Disciplined commercialization.
Strategic Partnerships & Funding
AltaSolvix engages with venture investors, state and federal funding agencies, and disease-focused foundations aligned with translational neurological innovation.
Non-Dilutive Funding
OEDIT, SBIR/STTR, and disease foundation grants aligned with our development milestones
Strategic Partners
Open to collaborations that accelerate our path toward IND-enabling development
IND-Enabling Path
Building toward regulatory milestones with structured, capital-efficient execution
Capital Discipline
Focused deployment toward defined technical inflection points and value creation
Certain technical and strategic details are available under NDA for qualified institutional partners.
Contact